Thermo Fisher Scientific Appoints Puerto Rico Partner Quality Instruments Solutions to Support Informatics Sales
News Dec 18, 2007
Thermo Fisher Scientific Inc. has established a new partnership with Puerto Rico-based distributor QIS to extend its informatics offerings in the Caribbean.
The new distribution agreement allows QIS to support sales activities in Puerto Rico and the wider Caribbean for the complete Thermo Scientific informatics product range, focusing on Laboratory Information Management Systems (LIMS) and Chromatography Data Systems (CDS).
The company says that, dedicated sales experts will target a number of industries which are strong in Puerto Rico, and which Thermo Fisher has long served, including the pharmaceutical, petrochemical and chemical markets.
QIS already successfully supplies and supports Thermo Scientific instruments in Puerto Rico, and aims to strengthen the company’s informatics offering in Puerto Rico through this new partnership. Customers will now have access to Thermo Fisher’s full informatics portfolio including Darwin LIMS™, Atlas CDS™, SampleManager™ and GRAMS™.
Oliver Faidi Cortés, director of Latin America and Caribbean sales for informatics at Thermo Fisher Scientific, comments, “This new partnership demonstrates our commitment to expanding and improving our services in Puerto Rico. We have served this region for more than 20 years, helping customers in a wide range of industries to improve production performance and quality while reducing operational costs.”
“QIS has developed a deep knowledge of local businesses, as well as of Thermo Fisher as a company. We feel that this perfectly positions QIS to promote and support our informatics portfolio for both new and existing customers.”
Milton Hernandez, President of QIS, confirms, “QIS focuses on the Puerto Rican market, with an experienced 15-strong team on the ground. QIS will offer sales, technical support and repairs to the island, bringing a local dedicated approach to the Thermo Fisher activity in the region.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019